Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.

The RAINIER trial met its primary endpoint, showing that povetacicept effectively reduces proteinuria in patients with immunoglobulin A nephropathy. Povetacicept, an investigational BAFF (B-cell ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Local lidocaine injection shows a similar early anesthetic effect in adults with Ehlers-Danlos syndrome and healthy ...

Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading ...

Johnson & Johnson's (JNJ) stock is in focus as the FDA approves a multiple myeloma therapy developed by the company with Halozyme (HALO). Read more here.

Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo ...

This once-weekly C-type natriuretic peptide analog functions by antagonizing overactive FGFR3 signaling to improve growth in pediatric patients.